Xuhui Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xuhui Kong has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Cangxue Wang
School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
1 shared publication- Cangxue Wang
School of Basic Medical Science, Zhengzhou University, Zhengzhou, China
1 shared publication - Caowei Sun
Zhengzhou Key Laboratory of Children’s Infection and Immunity, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, China
1 shared publication Chuanbo Sun
Laboratory of Medical Systems Biology, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, China
1 shared publicationDonghao Li
School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
1 shared publication- Donghao Li
School of Basic Medical Science, Zhengzhou University, Zhengzhou, China
1 shared publication
Latest Publications
- 21 October 2025
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 25 (1) , 1-19
CRLS1 influences liver metastasis in colon cancer by regulating lipid metabolism pathways
Colon cancer is one of the leading causes of cancer-related mortality, with liver metastasis commonly complicating its progression and significantly worsening patient prognosis. This study aims to explore the relationship between liver metastasis in colon cancer and various clinicopathological factors, as well as to investigate the underlying molecular mechanisms. The clinical data and weighted gene co-expression network analysis (WGCNA) were used to identify key genes associated with liver metastasis. The results revealed significant alterations in lipid metabolism associated with colon cancer progression. Notably, WGCNA and machine learning algorithms identified cardiolipin synthase 1 (CRLS1) as a hub gene robustly associated with liver metastasis in colon cancer. The expression of CRLS1 was assessed via scRNA-seq and the collection of clinical samples from colon cancer patients. CRLS1 knockdown significantly inhibited the proliferation and migration of colon cancer cells and suppressed lipid metabolism. Finally, several candidate drugs have been identified that may effectively target CRLS1. Moreover, it has been confirmed that the mTOR signaling pathway regulates CRLS1 expression, offering a promising avenue for future therapeutic strategies. In conclusion, this study highlights the pivotal role of CRLS1 in colon cancer and its potential as a biomarker and therapeutic target through lipid metabolism in managing this aggressive disease.
- 21 October 2025
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 25 (1) , 1-19
CRLS1 influences liver metastasis in colon cancer by regulating lipid metabolism pathways
Colon cancer is one of the leading causes of cancer-related mortality, with liver metastasis commonly complicating its progression and significantly worsening patient prognosis. This study aims to explore the relationship between liver metastasis in colon cancer and various clinicopathological factors, as well as to investigate the underlying molecular mechanisms. The clinical data and weighted gene co-expression network analysis (WGCNA) were used to identify key genes associated with liver metastasis. The results revealed significant alterations in lipid metabolism associated with colon cancer progression. Notably, WGCNA and machine learning algorithms identified cardiolipin synthase 1 (CRLS1) as a hub gene robustly associated with liver metastasis in colon cancer. The expression of CRLS1 was assessed via scRNA-seq and the collection of clinical samples from colon cancer patients. CRLS1 knockdown significantly inhibited the proliferation and migration of colon cancer cells and suppressed lipid metabolism. Finally, several candidate drugs have been identified that may effectively target CRLS1. Moreover, it has been confirmed that the mTOR signaling pathway regulates CRLS1 expression, offering a promising avenue for future therapeutic strategies. In conclusion, this study highlights the pivotal role of CRLS1 in colon cancer and its potential as a biomarker and therapeutic target through lipid metabolism in managing this aggressive disease.
- 30 May 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (6) , 2399-2410
Immunological Roles of CCL18 in Pan‑Cancer and Its Potential Value in Endometrial Cancer
Endometrial cancer (EC) is one of the most prevalent malignancies in the female reproductive system. However, the potential functions and mechanisms of immune-related genes in the onset and progression of EC remain unclear. The immune-related gene CCL18 has been implicated in apoptosis, proliferation, invasion, metastasis, and drug resistance in various types of tumors. Nevertheless, its role in pan-cancer has been poorly investigated, and its expression value and prognostic significance in endometrial cancer (EC) have not been explored. Therefore, the objective of this study was to identify potential immune-related prognostic biomarkers for EC by utilizing the cancer genome atlas (TCGA), immunology database and analysis portal (ImmPort) database, and Gene Expression Omnibus (GEO). Immunohistochemistry staining results from EC tissue chips demonstrated elevated expression levels of inflammatory chemokine protein 18 (CCL18) in EC compared to normal endometrium. This study offers a potential therapeutic strategy for EC treatment by identifying regulatory targets through microRNA sequencing data. Additionally, drug prediction was based on CCL18 targets. Furthermore, an analysis of CCL18 expression in pan-cancer was conducted, and the results revealed its high expression in various types of cancer, including EC and bladder cancer. Through analysis of the ATAC-seq data, we found that SIX1, SOX3, and TWIST2 may regulate CCL18 transcription by binding to the gene promoter of CCL18 in EC. This study indicated that CCL18 could be a potential biomarker in pan-cancer and EC.
- 30 May 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (6) , 2399-2410
Immunological Roles of CCL18 in Pan‑Cancer and Its Potential Value in Endometrial Cancer
Endometrial cancer (EC) is one of the most prevalent malignancies in the female reproductive system. However, the potential functions and mechanisms of immune-related genes in the onset and progression of EC remain unclear. The immune-related gene CCL18 has been implicated in apoptosis, proliferation, invasion, metastasis, and drug resistance in various types of tumors. Nevertheless, its role in pan-cancer has been poorly investigated, and its expression value and prognostic significance in endometrial cancer (EC) have not been explored. Therefore, the objective of this study was to identify potential immune-related prognostic biomarkers for EC by utilizing the cancer genome atlas (TCGA), immunology database and analysis portal (ImmPort) database, and Gene Expression Omnibus (GEO). Immunohistochemistry staining results from EC tissue chips demonstrated elevated expression levels of inflammatory chemokine protein 18 (CCL18) in EC compared to normal endometrium. This study offers a potential therapeutic strategy for EC treatment by identifying regulatory targets through microRNA sequencing data. Additionally, drug prediction was based on CCL18 targets. Furthermore, an analysis of CCL18 expression in pan-cancer was conducted, and the results revealed its high expression in various types of cancer, including EC and bladder cancer. Through analysis of the ATAC-seq data, we found that SIX1, SOX3, and TWIST2 may regulate CCL18 transcription by binding to the gene promoter of CCL18 in EC. This study indicated that CCL18 could be a potential biomarker in pan-cancer and EC.
- Open Access
- 14 March 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (12)
Endogenous retrovirus HERVH-derived lncRNAUCA1controls human trophoblast development
Endogenous retroviruses (ERVs) are frequently reactivated in mammalian placenta. It has been proposed that ERVs contribute to shaping the gene regulatory network of mammalian trophoblasts, dominantly acting as species- and placental-specific enhancers. However, whether and how ERVs control human trophoblast development through alternative pathways remains poorly understood. Besides the well-recognized function of human endogenous retrovirus-H (HERVH) in maintaining pluripotency of early human epiblast, here we present a unique role of HERVH on trophoblast lineage development. We found that the LTR7C/HERVH subfamily exhibits an accessible chromatin state in the human trophoblast lineage. Particularly, the LTR7C/HERVH-derivedUrothelial Cancer Associated 1(UCA1), a primate-specific long non-coding RNA (lncRNA), is transcribed in human trophoblasts and promotes the proliferation of human trophoblast stem cells (hTSCs), whereas its ectopic expression compromises human trophoblast syncytialization coinciding with increased interferon signaling pathway. Importantly,UCA1upregulation is detectable in placental samples from early-onset preeclampsia (EO-PE) patients and the transcriptome of EO-PE placenta exhibits considerable similarities to that of the syncytiotrophoblasts differentiated fromUCA1-overexpressing hTSCs, supporting up-regulatedUCA1as a potential biomarker of this disease. Altogether, our data shed light on the versatile regulatory role of HERVH in early human development and provide a unique mechanism whereby ERVs exert a function in human placentation and placental syndromes.
- 14 March 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (12)
Open AccessEndogenous retrovirus HERVH-derived lncRNAUCA1controls human trophoblast development
Endogenous retroviruses (ERVs) are frequently reactivated in mammalian placenta. It has been proposed that ERVs contribute to shaping the gene regulatory network of mammalian trophoblasts, dominantly acting as species- and placental-specific enhancers. However, whether and how ERVs control human trophoblast development through alternative pathways remains poorly understood. Besides the well-recognized function of human endogenous retrovirus-H (HERVH) in maintaining pluripotency of early human epiblast, here we present a unique role of HERVH on trophoblast lineage development. We found that the LTR7C/HERVH subfamily exhibits an accessible chromatin state in the human trophoblast lineage. Particularly, the LTR7C/HERVH-derivedUrothelial Cancer Associated 1(UCA1), a primate-specific long non-coding RNA (lncRNA), is transcribed in human trophoblasts and promotes the proliferation of human trophoblast stem cells (hTSCs), whereas its ectopic expression compromises human trophoblast syncytialization coinciding with increased interferon signaling pathway. Importantly,UCA1upregulation is detectable in placental samples from early-onset preeclampsia (EO-PE) patients and the transcriptome of EO-PE placenta exhibits considerable similarities to that of the syncytiotrophoblasts differentiated fromUCA1-overexpressing hTSCs, supporting up-regulatedUCA1as a potential biomarker of this disease. Altogether, our data shed light on the versatile regulatory role of HERVH in early human development and provide a unique mechanism whereby ERVs exert a function in human placentation and placental syndromes.